Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles(Queen Mary University of London), Petros Grivas(Seattle Cancer Care Alliance), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Howard Gurney(Radboud University Nijmegen), Srikala S. Sridhar(Princess Margaret Cancer Centre), Bo Huang(Inserm), Begoña P. Valderrama(Inserm), Se Hoon Park(Samsung Medical Center), Claudia Caserta(Inserm), Joaquim Bellmunt(Dana-Farber Cancer Institute), Anders Ullén(Inserm), Jing Wang(Qingdao University), Alessandra di Pietro(Inserm), Cora N. Sternberg(Cornell University), Robert J Laliberte(Inserm), Yohann Loriot(Institut Gustave Roussy)
Cited by 210
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k